methyl 2-(hydroxymethyl)-1,3-benzothiazole-5-carboxylate | 530145-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: methyl 2-(hydroxymethyl)-1,3-benzothiazole-5-carboxylate
• 英文别名: methyl 2-(hydroxymethyl)benzothiazole-5-carboxylate；5-Benzothiazolecarboxylic acid,2-(hydroxymethyl)-,methyl ester
• CAS: 530145-23-4
• 化学式: C₁₀H₉NO₃S
• 分子量: 223.252
• InChiKey: MKSXQKCCRMKXAU-UHFFFAOYSA-N

物化性质

• 沸点：
  372.0±22.0 °C(Predicted)
• 密度：
  1.413±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(hydroxymethyl)-1,3-benzothiazole-5-carboxylate 在 三溴化磷 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 2.58h， 生成 2-{[bis(2-methylpropyl)amino]methyl}-N-hydroxy-1,3-benzothiazole-5-carboxamide trifluoroacetate
  参考文献：
  名称：

  [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY
  [FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE

  摘要：

  化合物的化学式（Ia）或（Ib）或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。

  公开号：

  WO2017108282A1
• 作为产物：
  描述：

  3-氨基-4-氟苯羧酸甲酯 在 甲烷磺酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 196.0h， 生成 methyl 2-(hydroxymethyl)-1,3-benzothiazole-5-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY
  [FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE

  摘要：

  化合物的化学式（Ia）或（Ib）或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。

  公开号：

  WO2017108282A1

文献信息

• Novel benzophenone derivatives or salts thereof
  申请人：Chaki Hisaaki

  公开号：US20050113400A1

  公开（公告）日：2005-05-26

  A benzophenone derivative represented by the following formula: wherein R 1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R 2 represents, for example, a carboxyl group optionally protected with alkyl; R 3 represents, for example, an optionally protected hydroxyl group; R 4 represents, for example, an optionally substituted cycloalkyloxy group; and R 5 represents, for example, a hydrogen atom, or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

  以下是一种苯甲酮衍生物的化学式： 其中，R1代表例如可选取代的杂环基团或取代的苯基团；Z代表例如烷基链；R2代表例如可用烷基保护的羧基；R3代表例如可选保护的羟基；R4代表例如可选取代的环烷氧基团；R5代表例如氢原子或其盐。该化合物具有抗关节炎活性，能抑制由关节炎引起的骨破坏，并提供高安全性和优异的药代动力学，因此可用作治疗关节炎的药物。这些化合物具有抑制AP-1活性的作用，可用作预防或治疗与过度表达AP-1有关的疾病的药物。
• ANTIBACTERIAL AGENTS
  申请人：Brown David Ryall

  公开号：US20100173933A1

  公开（公告）日：2010-07-08

  Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R 1 )— or ═N—; R 1 is hydrogen or an optional substituent and R 2 is hydrogen, methyl, or fluorine; or R 1 and R 2 taken together are —CH 2 —, —CH 2 CH 2 —, —O—, or, in either orientation, —O—CH 2 — or —OCH 2 CH 2 —; R 3 is a radical of formula -(Alk 1 ) m -(Z) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.

  化学式为（I）的化合物具有抗菌活性：其中R代表氢或1、2或3个可选取代基；W是═C（R1）-或═N-；R1是氢或可选取代基，R2是氢、甲基或氟；或R1和R2一起取-CH2-、-CH2CH2-、-O-，或者，在任何方向上，取-O-CH2-或-OCH2CH2-；R3是公式-(Alk1)m-(Z)p-(Alk2)n-Q的基团，其中m、p和n独立地为0或1，但至少有一个为1，Z是-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-、-N（CH2CH3）-、-C（═O）-、-O-（C═O）-、-C（═O）-O-，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代双环杂环基团；Alk1和Alk2是可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可以以-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-或-N（CH2CH3）-结尾或被中断；Q是氢、卤素、腈或羟基，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团。
• Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
  申请人：KANCERA AB

  公开号：US10654814B2

  公开（公告）日：2020-05-19

  A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in therapy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

  式 (Ia) 或 (Ib) 的化合物 或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此可用于治疗，如治疗自身免疫性疾病、精神疾病、神经退行性疾病和过度增殖性疾病。
• NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1445249B1

  公开（公告）日：2012-11-07
• Creating an Antibacterial with in Vivo Efficacy: Synthesis and Characterization of Potent Inhibitors of the Bacterial Cell Division Protein FtsZ with Improved Pharmaceutical Properties
  作者：David J. Haydon、James M. Bennett、David Brown、Ian Collins、Greta Galbraith、Paul Lancett、Rebecca Macdonald、Neil R. Stokes、Pramod K. Chauhan、Jignesh K. Sutariya、Narendra Nayal、Anil Srivastava、Joy Beanland、Robin Hall、Vincent Henstock、Caterina Noula、Chris Rockley、Lloyd Czaplewski

  DOI：10.1021/jm9016366

  日期：2010.5.27

  3-Methoxybenzamide (1) is a weak inhibitor of the essential bacterial cell division protein FtsZ. Alkyl derivatives of 1 are potent antistaphylococcal compounds with suboptimal drug-like properties. Exploration of the structure activity relationships of analogues of these inhibitors led to the identification of potent antistaphylococcal compounds with improved pharmaceutical properties.